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Abstract
Objective. Endometrial cancer (EC) is the most frequent cancer of the female genital tract. It has been hypothesized that those ECs that occur in
the postmenopausal period, might be sensitive to elevated levels of luteinizing hormone/human chorionic gonadotropin (LH/hCG). Based on
previous indications, we analyzed the functional expression of LH/hCG receptors (LH/hCG-R) in primary ECs.
Methods. We studied a cohort of primary ECs, in which both the LH/hCG-R mRNA and the LH/hCG-R protein were analyzed. Results were
correlated with both clinical–pathological data and the effects of LH addition on cell invasion in vitro.
Results. The LH/hCG-R mRNA levels ranged from 4.67 e−02 to 2.36 e+03. The transcript was properly translated into a functional LH/hCG-R
protein. The analysis of cell invasion in vitro in response to LH/hCG allowed us to divide the EC samples into two groups, one with a null or very
low response (non-responders=NR) and the other with a significant response to LH (responders=R). The two groups had significantly different
levels of LH/hCG-R mRNA expression: the NR group had a median value of 1.40 e+00, while the R group of 7.42 e+01 (p=0.043).
Conclusion. In primary ECs a statistically significant correlation emerged between the levels of LH/hCG-R mRNA and the LH-induced cell
invasion in vitro. These results suggest that therapies aimed at decreasing LH levels, through Gonadotropin Releasing Hormone (Gn-RH)
analogues, could produce benefits in the treatment of recurrent or metastatic EC, especially in patients displaying high LH/hCG-R levels.
© 2008 Elsevier Inc. All rights reserved.
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Introduction
Endometrial cancer (EC) is currently the most frequent
malignancy of the female reproductive tract [1]. EC is a curable
malignancy, with a good prognosis and an overall survival rate
of about 80%. This is mainly due to the fact that the majority of
cases are diagnosed in the early stages (International Federation
of Gynecology and Obstetrics (FIGO) Stage I). However, there
is a group of patients with a high risk of cancer recurrence or
metastatic spread. In particular, those cancers arising in women
in an advanced menopausal phase are often more aggressive
and apparently independent from estrogen (E) secretion [2].
The latter, especially when unlinked to progesterone, is
apparently one of the most relevant etiologic factors in EC
[3], since Es contribute to the malignant transformation through
a potent mitogenic effect on the endometrial surface epithelium
[4]. It was hypothesized that E-independent ECs might be
sensitive to the elevated levels of luteinizing hormone/human
chorionic gonadotropin (LH/hCG) that characterize the post-
menopause. Hence, gonadotropins might be involved in the
natural history of at least some types of ECs. This hypothesis
was indirectly supported by the demonstration that the LH/
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hCG-receptor (LH/hCG-R) gene was expressed in human ECs
[3] and that the addition of LH/hCG regulates proliferation in
EC cell lines [5]. On these bases some clinical trials were
performed with the aim of treating patients affected by EC with
gonadotropin releasing hormone (Gn-RH) analogues, in order
to decrease LH levels. Conflicting results emerged from these
studies [5–11].
We performed a study that showed the functional expression
of LH/hCG-R in the moderately differentiated EC cell line
Hec1A [12]. At a difference from what was reported for
Ishigawa cells [13], the addition of LH/hCG to Hec1A cells
induces an increase of cell invasion through Matrigel, which is
mediated by the activation of protein kinase A. We also
provided preliminary evidence that the LH/hCG-R mRNA is
expressed in primary EC and that primary EC cells can be
triggered to invade Matrigel by LH addition, through a PKA-
dependent mechanism [12].
To confirm and deepen these results, we studied a larger
cohort of primary ECs, in which the quantitative expression
of LH/hCG-R mRNA and the presence of the LH/hCG-R
protein were analyzed. Results were correlated with clinical–
pathological data as well as with the effects of LH addition on
cell invasion in vitro.
Materials and methods
Chemicals
MATRIGEL® Basement Membrane Matrix by Becton
Dickinson Labware (Becton Dickinson) was used at a final con-
centration of 250 μg/ml following the instructions. Anti-LH-R
(Santa Cruz Biotechnology) (WB: 1:300); anti-αTubulin (WB:
1:500), anti-rabbit peroxidase-conjugate (Sigma) (1:10000),
anti-mouse peroxidase-conjugate (1:5000) antibodies are all
from Sigma. hrLH Luveris® (Lutropina alfa) 75 UI (3.4 μg)
(Serono Laboratoires) was used at 0.3 UI/ml [12]. The mono-
clonal antibody anti LH-R 3B5was provided by Dr.Wimalasena
and used at a 1:50 final dilution.
Clinical data
Tissue samples were obtained after informed written consent
from 25 consecutive patients who underwent radical surgery with
curative intent for primary EC at the Department of Gynecology,
Perinatology and Human Reproduction, University of Florence.
Uterus was removed and sampling of neoplastic tissue was
immediately performed.
Matrigel invasion assay
Cell suspension from primary samples performed as in
[14], were resuspended in DMEM containing 250 μg/ml of
heat inactivated BSA (DMEM+BSA). The Matrigel invasion
assay was performed as previously described [12]. Due to
the different sizes of tissue biopsies, variable concentrations
of cells were used (from 50 to 400×103 cells/ml). Four
pivotal experiments were performed to ensure that different
concentrations in the cell suspension did not interfere with
experimental results.
Immunohistochemistry (IHC)
IHC was performed on 7 μm sections adhered on positive-
charged microscope slides. The 3B5 monoclonal antibody was
diluted in UltraVBlock (LabVision): PBS 1:10 (v/v). Detection
was carried out using a commercially available kit (PicTure Plus
Kit, Zymed) as well as DAB chromogen solution (Zymed),
according to the manufacturer's instructions.
RNA extraction and reverse transcription-polymerase chain
reaction (RT-PCR)
RNAwas promptly extracted from cell suspensions obtained
from fresh tissue sample as in [12].
Real-Time Quantitative PCR (RQ-PCR)
LH/hCG-R mRNAwas quantified by RQ-PCR, with the ABI
PRISM 7700 Sequence Detection System (Applied Biosystem).
The β-glucuronidase (GUS) gene was used as standard reference.
The relative expression of LH/hCG-R was calculated by using a
comparative threshold cycle method. Standard curves were pre-
pared using 10 fold serial dilutions of cDNA retrotranscribed from
testis, which represent a positive control for LH/hCG-R. The
primer sequences were as follows: LH/hCG-R: sense GCAGAA-
GATGCACAATGGAG; antisense CTCTCAGCAAGCATGGA-
AGA; GUS sense GAAAATATGTGGTTGGAGAGCTCATT;
antisense CGGAGTGAAGATCCCCTTTTTA. The primers were
used at a final concentration of 300 nM for both GUS and LH/
hCG-R. Each PCR program startedwith an incubation at 95 °C for
10 min, followed by 40 cycles of amplification, each involving an
annealing–extension step at 60 °C for 1 min and denaturation at
95 °C for 15 s. To exclude contamination of unspecific PCR
products, melting curve analysis was always applied to final PCR
products after the cycling protocol.
Protein extraction and Western blot
Protein extraction and Western blots were performed as
reported in Crociani et al. [15], loading 60 μg of protein
extracts. The immunoreactivity was determined by an enhanced
chemiluminescent reaction (Super Signal; Pierce).
Statistical methods
Statistical analysis was carried out using Stata software
(9.1 version, Statacorp; College Station). The Anova test and the
T-test were used to assess whether the means of two independent
groups were statistically different from each other. The rela-
tionships between LH/hCG-R mRNA expression and IHC data
and clinical features (post-operative histology, grading and
myometrial infiltration) were evaluated through the Fisher's
exact test. P values less than 0.05 were considered statistically
significant.
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Results
We collected twenty five consecutive samples from patients
who underwent radical surgery with curative intent for primary
EC. The clinical–pathological characteristics of the patients are
reported in Table 1.
We first determined the expression of LH/hCG-R mRNA by
nested PCR in all the samples examined (not shown).
Subsequently, a quantitative estimate of LH/hCG-R mRNA
was performed by Real-Time Quantitative PCR (RQ-PCR). In
Fig. 1A are reported the typical RQ-PCR amplification curves
of LH/hCG-R (top) and of the control gene GUS (bottom) on
representative endometrial samples. A signal of LH/hCG-R
from EC can be observed starting from cycle 17, evidencing that
LH/hCG-R is indeed expressed in EC. Panel 1B illustrates
dissociation curves from a representative run: the dissociation
curve plot displays a characteristic melting peak typical of a
single target nucleic acid sequence, confirming the specificity of
the reaction. The levels of the LH/hCG-R transcript calculated
as reported in Materials and methods, were normalized on the
levels of the corresponding transcript detected in Hec1A cells.
Data obtained through this method showed that the range of
LH/hCG-R mRNA expression in EC strongly varied among the
different samples. In fact levels of the transcript ranged from
4.67 e−02 to 2.36 e+03, with a median value of 4.00 e+ 01 (see
Fig. 1C).
We then confirmed the proper translation of the LH/hCG-R
mRNA through a WB analysis performed in some of the
samples collected (Fig. 2A). The blots showed the presence of
two protein bands weighting 85 and 75 kDa, respectively, both
attributable to the LH/hCG-R. These two bands represent the
mature and the immature forms of the receptor, respectively
[16–19]. Hence, the LH/hCG-R protein is expressed both in
normal and neoplastic endometrium. The quantitative analysis,
comparing the LH/hCG-R bands with those of tubulin, indicates
that the LH/hCG-R is expressed at higher levels in adenocarci-
noma samples as compared to normal mucosa, confirming what
was previously reported by Rao et al. [20].
An IHC analysis was also performed on paraffin embedded
samples of the tumours collected. In Fig. 2B representative
immunostaining patterns of LH-R expression in four EC
specimens are reported. In any case, the positive staining is
shown as a brown pigment, with a blue nuclear hematoxylin
counterstain. A human testis specimen, which shows a strong
intensity of LH-R labelling, is reported in the inset to panel 1, as
positive reference. Samples in panels 1 and 2 display a good and
diffuse staining, mainly localized in the cytoplasm and plasma
membrane of epithelial cells (see arrows), although a faint
signal can be also detected in stromal cells. The sample in
panel 3 shows a moderate staining, largely confined to the
glandular epithelium (see arrow), whereas a sample negative for
LH/hCG-R is reported in panel 4. All the results of the IHC
analysis are summarized in Table 1 and reported as − (no
immunostaining) or + (positive immunostaining). The IHC
analysis showed that 65% (15/23) of EC samples expressed the
LH/hCG-R. No statistically significant correlation emerged
Table 1
Patients' characteristics, LH-R expression and effect of LH on cell invasion
Patient Age Post-operative histology Grading LH/hCG-R
expression (IHC)
Cell invasion (untreated
samples) (mean±SEM)
Cell invasion (LH-treated
EC samples) (mean±SEM)
Effect of LH on cell
invasion (% of control)
1 68 EA G1 + 442.5±43.5 463.3±133.83 105
2 64 EA G1 − 55±18 93.3±16 170
3 78 EA G3 + 90.3±17 154±5 170
4 64 EA G2 + 71.7±13.2 74±16.56 103
5 59 EA G2 + 28.7±7.3 74±26 258
6 65 PSC G3 − 233±33 304±44.3 130
7 56 EA G2 + 18±1 27±16 150
8 63 EA G2 + 229±48.2 252.5±91.5 110
9 73 EA G3 − 25.8±3 38±12 147
10 64 EA G2 + 130±21 212±36 163
11 80 EA G1 + 42.5±12 53.3±9.6 125
12 77 EA G2 . 76.3±17.8 195.3±21.7 256
13 67 EA G2 − 142.7±24.8 319.7±59.8 224
14 71 EA nd − 10.3±1.7 14.5±4 140
15 67 EA G1 − 63.3±9.7 63.4±5.7 100
16 49 EA G3 + 237.3±53.3 238±54.6 100
17 56 EA G3 + 263±24 316±97 120
18 72 EA G2 + 115±18 216±68 188
19 70 PSC G3 . 10.9±0.8 9.5±0.8 88
20 56 EA G2 − 9±3.7 16.2±5.1 180
21 63 EA G3 − 50±6.8 45±11 90
22 62 EA nd − 22±2 19.7±4 90
23 67 EA G1 + 23±11 54±14 235
24 71 EA G3 + 12±2.5 13.2±2.2 110
25 55 EA G2 − 112.7±3.7 135±26.5 120
Clinical–pathological characteristics of the patients enrolled in the study are reported. LH/hCG-R expression (IHC) is shown as − (no immunostaining) or + (positive
immunostaining). Cell invasion assay results are shown as the mean±SEM before and after LH addition and as folds of increase.
EA: endometrioid adenocarcinoma; PSC: Papillary Serous Carcinoma; nd=not determined.
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between IHC and RQ-PCR data (p=0.58), nor of RQ-PCR or
IHC data with the clinical–pathological characteristics of the
patients (post-operative histology, grading and myometrial
infiltration) (Fig. 3A).
Based on previous data [12], we evaluated the effect of LH
addition on cell invasion through Matrigel in all the primary
samples collected. Results are shown in Table 1, where both the
values before and after LH addition (mean±SEM) and the
percentage increase of cell invasion after LH addition are
reported. The response to LH addition varied among the
different samples: some were almost unaffected by LH addition,
while others displayed a 2/2.5 fold increase in cell invasion after
LH addition. Using a cut-off close to the median value of the
percentage increase of cell invasion after LH addition we divi-
ded the entire EC population into two groups, one with a null or
very low response to LH (≤1.2 fold) (non-responders=NR) and
the other with a significant response to LH addition (N1.2 fold)
(responders=R). The two groups had significantly different
levels of LH/hCG-R mRNA expression (Fig. 3B). In fact, the
median value of the NR group was 1.40 e+ 00, while that of the
R group was 7.42 e+ 01 (p=0.043).
Discussion
In the present paper we measured LH/hCG-R expression at
both the mRNA and protein levels in a cohort of primary ECs.
LH/hCG-R expression was analyzed in conjunction with
clinical–pathological features of the samples collected, as well
as with the effects of LH addition on cell invasion in vitro. The
main result that emerged from our study was a statistically
Fig. 1. LH/hCG-R expression in primary EC samples. RNAwas extracted from cell suspension obtained from fresh EC samples. RQ-PCR was performed using the
Sybr Green method. (A) LH/hCG-R (upper panel) and GUS (lower panel) real-time PCR application curves. Each curve was generated in triplicate from the same
sample. (B) Dissociation curves of the samples analyzed by RQ-PCR. The plot of the first derivative of the rate of change in fluorescence as a function of temperature is
shown. (C) LH/hCG-R mRNA expression levels in all the patients enrolled in the study.
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significant correlation between LH/hCG-R mRNA expression
and the LH-induced increase in cell invasiveness.
Using the Sybr Green technique we showed that the amount
of LH/hCG-R expressed in primary EC varied from 4.67 e−02 to
2.36 e+03. This finding agrees with previous data obtained with
TaqMan Real-time PCR [21], hence confirming that Real-Time
PCR is a good and reliable method to detect and quantify the
LH/hCG-R expression in endometrial tissues.
The receptor was properly translated and expressed in EC
cells. This was demonstrated by both WB and IHC experiments.
The latter showed that almost 65% of the cases are positive.
Collectively, these results confirmed the presence of the LH/
hCG-R in endometrial adenocarcinomas, as previously reported
by Rao et al. [20] and by our group [12].
Previous results from our group [12], showed the relevance
of the pathway centred on LH binding to its receptor on EC cells
in the regulation of a relevant aspect of tumour progression, i.e.
the invasion of surrounding tissues. These results were obtained
in a moderately differentiated EC cell line, Hec1A, as well as on
a few EC primary samples; in both cases the capability of
invading in response to LH addition was dependent on PKA
activation [12]. We here provide evidence that in a large number
of primary EC samples the LH-induced cell invasion in vitro
positively correlates with the amount of LH/hCG-R mRNA,
while no correlation emerged between the amount of the
receptor and other clinical–pathological characteristics of the
patients.
On the whole, our data, along with those showing that LH/
hCG regulates VEGF secretion [22], tend to configure the LH/
hCG gonadotropin as a progression factor in EC, contributing to
regulate cell invasion and angiogenesis, and hence ultimately
leading to metastatic spread. Results here presented shed light to
reconcile the conflicting results present in the literature, about
the clinical effect of LH analogues in the treatment of recurrent
or metastatic EC. We in fact report that only 35% of patients
showed a high expression of LH/hCG-R mRNA. Interestingly,
only these patients respond to exogenous recombinant LH
addition by increasing the cell invasion through Matrigel. This
could in turn imply that only such patients could receive
benefits from a therapy aimed at decreasing LH levels, for
example, through Gn-RH analogues. We hence prospect to
analyze herein all the IV stage patients (whose 5 year survival is
Fig. 2. Expression of LH/hCG-R. (A) LH/hCG-R protein expression in normal and neoplastic endometrium analyzed by WB. Total lysate from samples were blotted
and probed with an anti-LH-R specific antibody. The top bands, weighting 85 kDa refer to the mature forms of the receptor, the bottom bands weighting 75 kDa refer to
the immature forms of the receptor. Reprobing of the membrane with anti-Tubulin antibody is reported in the bottom panel. (B) Immunohistochemistry for the
LH/hCG-R protein on four representative EC specimens (panels 1–4) and a testicular biopsy as a positive control (inset).
Fig. 3. Correlation between LH/hCG-R expression and features of EC samples.
(A) Correlation between LH/hCG-R expression (both RQ-PCR and IHC data)
and clinical features (post-operative histology, grading and myometrial
infiltration) of EC primary samples. Data were analyzed through the Fisher's
exact test. In the last line the statistical analysis of data reported in panel B is
shown. For the analysis of the correlation between RQ-PCR and IHC data two
different RQ-PCR groups (transcript expression ≤0, transcript expression N0)
and two different IHC groups were identified. (B) LH/hCG-R expression in non-
responder (NR) and responder (R) samples. EC population was divided into two
groups, one with a null (or very low) response to LH (≤1.2 fold) (NR) and the
other displaying a significant response to LH addition (R) (original data are
reported in Table 1). Median value NR group: 1.40 e+00; median value HR
group: 7.42 e+01. Each circle represents an EC sample.
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less than 10%) for the expression of LH/hCG mRNA and treat
only the high expressors with Gn-RH analogues.
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